
Tenaya Therapeutic (TNYA) Stock Forecast & Price Target
Tenaya Therapeutic (TNYA) Analyst Ratings
Bulls say
The financial outlook for Tenaya Therapeutics Inc appears positive due to recent advancements in their product candidates, particularly the increased projected chances of success for TN-201 and TN-401, which have been raised to 30% and 15% respectively. Consistent improvements in left ventricular mass index (LVMI) and left ventricular posterior wall thickness (LVPWT) in patients could pave the way for accelerated approval pathways, aligning the company with the achievements of peer cardiac gene therapy programs. Additionally, promising data on cardiac biomarkers and patient classification stability indicates potential for continued clinical efficacy, further reinforcing the company's strong position in the biotechnology sector.
Bears say
Tenaya Therapeutics faces significant risks that could adversely affect its market outlook, primarily due to potential delays in transitioning its preclinical assets to clinical trials and the possibility of emerging safety signals, such as immune reactions. Moreover, the company's ability to manufacture its therapeutic products may limit its operational capacity and negatively impact financial forecasts. These factors contribute to a fundamentally negative sentiment surrounding Tenaya's stock performance.
This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.
Tenaya Therapeutic (TNYA) Analyst Forecast & Price Prediction
Start investing in Tenaya Therapeutic (TNYA)
Order type
Buy in
Order amount
Est. shares
0 shares